X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 35.4 -2.5 - View Chart
P/BV x 9.1 0.1 9,682.7% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
VENUS REMEDIES
Mar-18
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs6,110126 4,853.1%   
Low Rs3,99661 6,540.1%   
Sales per share (Unadj.) Rs1,552.2301.8 514.3%  
Earnings per share (Unadj.) Rs188.8-24.9 -759.2%  
Cash flow per share (Unadj.) Rs196.42.5 7,719.3%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.6293.3 271.6%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 1,050.7%   
Avg P/E ratio x26.8-3.8 -711.9%  
P/CF ratio (eoy) x25.736.7 70.0%  
Price / Book Value ratio x6.30.3 1,989.7%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,154 9,306.4%   
No. of employees `0003.30.9 359.1%   
Total wages/salary Rs m3,937393 1,001.5%   
Avg. sales/employee Rs Th9,929.34,026.1 246.6%   
Avg. wages/employee Rs Th1,185.1425.0 278.9%   
Avg. net profit/employee Rs Th1,207.7-331.8 -364.0%   
INCOME DATA
Net Sales Rs m32,9853,724 885.7%  
Other income Rs m1,17023 5,199.6%   
Total revenues Rs m34,1553,747 911.6%   
Gross profit Rs m5,245395 1,328.5%  
Depreciation Rs m162338 47.9%   
Interest Rs m38354 10.8%   
Profit before tax Rs m6,215-275 -2,257.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,20332 6,970.6%   
Profit after tax Rs m4,012-307 -1,307.3%  
Gross profit margin %15.910.6 150.0%  
Effective tax rate %35.4-11.5 -308.8%   
Net profit margin %12.2-8.2 -147.6%  
BALANCE SHEET DATA
Current assets Rs m22,6552,638 858.9%   
Current liabilities Rs m6,6812,305 289.9%   
Net working cap to sales %48.48.9 541.5%  
Current ratio x3.41.1 296.3%  
Inventory Days Days65135 47.8%  
Debtors Days Days2946 62.9%  
Net fixed assets Rs m8354,871 17.2%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m16,7153,496 478.2%   
Net worth Rs m16,9283,619 467.7%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m24,1627,509 321.8%  
Interest coverage x163.70.2 73,412.4%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.40.5 275.2%   
Return on assets %16.80.6 2,655.4%  
Return on equity %23.7-8.5 -279.5%  
Return on capital %36.91.6 2,334.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3690-   
Fx outflow Rs m3,807517 737.0%   
Net fx Rs m-3,438-517 665.6%   
CASH FLOW
From Operations Rs m1,527514 296.9%  
From Investments Rs m-2,148-123 1,745.2%  
From Financial Activity Rs m-1,024-387 264.6%  
Net Cashflow Rs m-1,6464 -39,181.0%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  UNICHEM LAB  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 311 Points Lower; Consumer Durables and Energy Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended their trading session lower. Barring telecom sector and realty sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)

Feb 5, 2019

A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 18, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PLETHICO PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS